Tuberculosis burden in Lebanon: Evolution and current status

Journal Medical Libanais

Volumn 64, Issue 1, 2016, Pages 1-7

  Araj, George F ^a   Saade, Antoine ^b,c   Itani, Lina Y ^a   Avedissian, Aline Z ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b MINISTRY OF PUBLIC HEALTH   (Lebanon)

^c Lebanese Anti Tuberculosis Association (LATA)   (Lebanon)

Author keywords

Epidemiological aspect; High risk groups; MDR TB; MOTT; Tb burden in Lebanon

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN;

ARTICLE; CHILD; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LEBANESE; LEBANON; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM OTHER THAN TUBERCULOSIS; MYCOBACTERIUM SIMIAE; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; PRISONER; REGISTER; RETROSPECTIVE STUDY; SEX RATIO; TREND STUDY; TUBERCULOSIS; ADOLESCENT; ADULT; CLASSIFICATION; HIV INFECTIONS; MIDDLE AGED; MYCOBACTERIUM; PRISON; REFUGEE; STATISTICS AND NUMERICAL DATA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADOLESCENT; ADULT; CHILD; FEMALE; HIV INFECTIONS; HUMANS; LEBANON; MALE; MIDDLE AGED; MYCOBACTERIUM; PRISONS; REFUGEES; RETROSPECTIVE STUDIES; SEX DISTRIBUTION; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84978410077     PISSN: 00239852     EISSN: None     Source Type: Journal    
DOI: 10.12816/0023824     Document Type: Article

References (36)

1. WHO. Global tuberculosis report 2013. Geneva (Switzerland): World Health Organization; 2013.
2. Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N Engl J Med 2013; 368: 745-55.
3. Araj GF, Talhouk RS, Itani LY, Jaber W, Jamaleddine GW. Comparative performance of PCR-based assay vs microscopy and culture for the direct detection of Mycobacterium tuberculosis in clinical respiratory specimens in Lebanon. Intl J Antimic Agents 1999; 11: 47-52.
4. Hamzeh MM, Araj GF. Drug resistance among Mycobacterium tuberculosis in Lebanon. Intl J Tuber Lung Dis 1997; 1: 314-18.
5. Araj GF, Itani LY, Kanj NA, Jamaleddine GW. Comparative study of antituberculous drug resistance among Mycobacterium tuberculosis recovered at the American University of Beirut Medical Center: 1996-98 vs 1994- 95. Leb Med J 2000; 48: 18-22.
6. Araj GF, Saade M, Itani LY. Nationwide study of drug resistance among acid-fast bacilli smear positive pulmonary tuberculosis cases in Lebanon. Intl J Tuber Lung Dis 2006; 10: 63-7.
7. Van Rie A, Warren R, Mshanga I et al. Analysis for a limited number of gene codons can predict drug resistance of Mycobacterium tuberculosis in a high-incidence community. J Clin Microbiol 2001; 39: 636-41.
8. Ahmad S, Araj GF, Akbar PK, Fares E, Chugh TD, Mustafa AS. Characterization of rpoB mutations in rifampin-resistant Mycobacterium tuberculosis isolates from the Middle East. Diag Microbiol Infec Dis 2000; 38: 227-32.
9. Ahmad S, Mokaddas E, Abal AT, Araj GF, Fares E, Mustafa AS. Genetic polymorphism at codon 463 in thekatG gene in isoniazid-sensitive and -resistant isolates of Mycobacterium tuberculosis from the Middle East. Med Prin Pract 2001; 10: 129-34.
10. Ahmad S, Fares E, Araj GF, Chugh TD, Mustafa AS. Prevalence of S315T mutation within the kat G gene in isoniazid-resistant clinical Mycobacterium tuberculosis isolates from Dubai and Beirut. Intl J Tuber Lung Dis 2002; 6: 920-6.
11. Ahmad S, Itani LY, Araj GF. Molecular fingerprinting of multidrug-resistant Mycobacterium tuberculosis in Beirut reveals genetic diversity and father to daughter transmission. Leb Med J 2003; 5: 4-8.
12. Ahmad S, Itani LY, Fares E, Araj GF. Varying prevalence of embB codon 306 mutations in ethambutol-resistant clinical Mycobacterium tuberculosis isolates from Beirut and Dubai. J Chemother 2008; 20: 285-7.
13. Areeshi MY, Bish SC, Mandal RK, Haque S. Prevalence of drug resistance in clinical isolates of tuberculosis from GCC: A literature review from January 2002 to March 2013. J Infect Dev Ctries 2014; 8: 1137-47.
14. Lynch JB. Multidrug-resistant tuberculosis. Med Clin N Am 2013; 97: 553-79.
15. LoBue P. Extensively drug-resistant tuberculosis. Curr Opin Infec Dis 2009; 22: 167-73.
16. Migliori GB, De Iaco G, Besozzi G, Centis R, Cirillo DM. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 2007; 12: E070517.
17. Velayati AA, Masjedi MR, Farnia P et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009; 136: 420-5.
18. Shah NS, Richardson J, Moodley P et al. Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa. Emerg Infect Dis 2011; 17: 510-13.
19. Udwadia ZF. MDR, XDR, TDR tuberculosis: ominous progression. Thorax 2012; 67: 286-8.
20. Pietersen E, Ignatius E, Streicher EM et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: A cohort study. Lancet 2014; 383: 1230-9.
21. Schnippel K, Rosen S, Shearer K et al. Costs of inpatients treatment for MDR-TB in South Africa. Trop Med Int Health 2013; 18: 109-16.
22. Barclay L. CDC issues plan to combat extensively drugresistant tuberculosis. MMWR 2009; 58 (RR03): 1-43.
23. Hoefsloot W, van Ingen J, Andrejak C et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: An NTM-NET collaborative study. Eur Respir J 2013; 42: 1604-13.
24. Ringshausen FC, Apel RM, Bange FC et al. Burden and trends of hospitalisations associated with pulmonary NTM infections in Germany, 2005-2011. BMC Infect Dis 2013 May 21; 13: 231.
25. Bou Fakhreddine HM, Kanj AN, Kanj NA. The growing epidemic of water pipe smoking: Health effects and future needs. Respiratory Medicine 2014; 108: 1241-53.
26. th Annual Meeting of the American Society for Microbiology, Philadelphia, USA, May 17-21, 2009. Abstract U-001.
27. Abbas O, Marrouch N, Kattar MM et al. Cutaneous nontuberculous mycobacterial infections: A clinical and histopathological study of 17 cases from Lebanon. J Europ Acad Derm Vener (JEADV) 2011; 25: 33-44.
28. Atallah D, El Kassis N, Araj G et al. Mycobacterial infection of breast prosthesis - A conservative treatment Mycobacterium canariasense. BMC Infectious Diseases 2014; 14: 238.
29. Huminer D, Dux S, Samra Z et al. Mycobacterium simiae infection in Israeli patients with AIDS. Clin Infect Dis 1993; 17: 508-9.
30. Valero G, Peters J, Jorgensen JH, Graybill JR. Clinical Isolates of Mycobacterium simiae in San Antonio, Texas: An 11-yr review. Am J Resp Crit Care Med 1995; 152: 1555-7.
31. Richter E, Brown-Elliott BA, Wallace RJ Jr. Mycobacterium: laboratory characteristics of slowly growing mycobacteria. In: Versalovic J et al. ed. Manual of Clinical Microbiology, 10th ed. Washington DC: American Society for Microbiology, 2011: 503-24.
32. Balkis MM, Kattar MM, Araj GF, Kanj SK. Fatal disseminated Mycobacterium simiae infection in a non-HIV patient. Intl J Infect Dis 2009; 13: E286-e287.
33. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Amer J Respir Crit Care Med 2005; 172: 1169-227.
34. Itani LY, Cherry MA, Araj GF. Efficacy of BACTEC TB in the rapid diagnosis of mycobacterial infections. A Lebanese tertiary care center experience. Leb Med J 2005; 53: 208-12.
35. Steingart KR, Sohn H, Schiller I et al. XpertR MTB/RIF assay for pulmonary tuberculosis and rifampin resistance in adults. Cochrane Database Syst Rev. 2013 Jan 31, 1:CD009593.
36. Frieden TR, Brudney KF, Harries AD. Global Tuberculosis: Perspectives, Prospects, and Priorities. JAMA 2014; 312: 1393-4.